Mini Review

**HOX Genes as Potential Markers of Circulating Tumour Cells**

Richard Morgan and Mohamed El-Tanani

Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, UK

Running title: **HOX Genes and CTCs**

**Keywords:** Circulating tumour cells; HOX gene; biomarker

**Abbreviations**

CTC, circulating tumour cell

EpCam, epithelial cell adhesion molecule
Abstract

Circulating tumour cells (CTCs) have significant diagnostic potential as they can reflect both the presence and recurrence of a wide range of cancers. However, this potential continues to be limited by the lack of robust and accessible isolation technologies. An alternative to isolation might be their direct detection amongst other peripheral blood cells, although this would require markers that allow them to be distinguished from an exceptionally high background signal. This review assesses the potential role of HOX genes, a family of homeodomain containing transcription factors with key roles in both embryonic development and oncogenesis, as unique and possibly disease specific markers of CTCs.
Introduction

Circulating tumour cells (CTCs) have been identified for a wide range of cancers types, although notable examples include breast [1], prostate [2], colorectal [3], and lung cancer [4]. In addition to providing a mechanistic explanation for widespread disease dissemination, they also represent a potential biomarker for diagnosis and prognosis. Hence, for example in breast cancer the presence of CTCs is an independent prognostic factor for both progression-free survival and overall survival, and a cut-off of 5 CTCs / 7.5 ml has been used to identify patients with a good or poor prognosis [5]. In addition, the persistence of CTCs after adjuvant therapy for breast cancer is significantly associated with a shorter disease-free survival.

Although CTCs are a potentially useful biomarker, an intrinsic difficulty of this approach is their rarity, and their identification requires a combination of enrichment and detection strategies. The latter is based on technologies that can distinguish CTCs from blood cells based on their physical (e.g. size, density, electrical charge and deformability), and biological properties (e.g. cell surface protein expression and viability). Ficol gradients are one of the simplest and earliest methods used to separate CTCs, but other available methods include the use of dielectrophoretic technology to exploit differences in the biophysical properties of CTCs and blood cells [6], and label-free chips that separate CTCs based on their size [7]. Most techniques used to enrich CTCs are based on the expression of distinct cell surface markers that can be immunologically detected. The most commonly exploited cell surface marker is the epithelial cell adhesion molecule (EpCam), which is central to a range of antigen-capture based techniques such as CellSearch® and CTC-CHIP [8, 9]. However, there are no uniformly expressed CTC markers, and EpCam itself is not present on all CTCs, most notable because it is down regulated during the epithelial-to-mesenchymal transition, a process that is central to metastatic change [10].
An alternative to CTC isolation could be the identification of gene expression patterns that are not present in blood cells. This would inevitably be complicated by the vast excess of RNA from white blood cells in any preparation made from whole blood. However, sensitive detection methods for identifying a small number of transcripts, for example quantitative PCR (qPCR), could allow CTCs to be identified, as well as potentially the cancer from which they originated, if specific patterns of gene expression could be established that are not presented by white blood cells. One particularly strong candidate in this respect is the HOX gene family.

**HOX genes**

The HOX genes are a family of homedomain-containing transcription factors that have a crucial role in the patterning of the early embryo, as well as some more limited functions in adult physiology. There are 39 HOX genes in the human genome present in 4 separate genomic clusters, named A-D, which arose from a series of duplication events prior to the emergence of mammals [11]. Unusually, genes within each cluster share enhancer regions, leading to a closely coordinated pattern of expression during development and a close relationship between the position of each HOX gene in the cluster and its temporal and spatial expression. Thus, for example, the 3’ most member of the HOXB cluster, HOXB1, is expressed earlier and more anteriorly than one of the most 5’ members, HOXB9 [12]. HOX proteins have relatively limited specificity for DNA, binding to a 4 base pair sequence. Their binding specificity and hence target gene activation (or in some cases repression) is greatly enhanced by their interaction with specific co-factors such as PBX and MEIS proteins [13, 14].

During early development, HOX gene products help to define the identity of the tissues in which they are expressed, principally along the anterior to posterior axis. These tissues include the nervous system posterior to the midbrain, the gut, and the limbs [11]. In addition, some adult cells continue
to express *HOX* genes and in these cells *HOX* expression is necessary to maintain cellular identity, and in some cases is also needed for continued cell proliferation and survival. One of the best characterized examples is the hematopoietic stem cell and its differentiated progeny. *HOXB4* is required for the continued proliferation of hematopoietic stem cells, and once their daughter cells subsequently begin to differentiate through the long cascade of hematopoietic progenitor cell types they express different *HOX* genes in nested patterns, with the mature lymphocytes expressing quite distinct patterns of *HOX* genes compared to the parental stem cells [15].

**HOX genes in cancer**

In addition to their function in the embryo and in some normal adult cells, the *HOX* genes also have a key function in malignancy. This has been reviewed extensively elsewhere, but in brief, the *HOX* genes are frequently dysregulated in almost all of the solid and haematological malignancies in which they have been studied [16]. A number of them have been shown to function as oncogenes, including *HOXA9*, the forced expression of which in normal mouse bone marrow cells leads to acute myeloid leukaemia within 3 months [17]. Many other *HOX* genes have been shown to have a pro-oncogenic role in terms of supporting tumour growth. *HOX* proteins can promote cell proliferation and survival through interaction with the PBX co-factor, and the disruption of *HOX/PBX* dimer formation using the HXR9 peptide has been shown to trigger apoptosis in a wide range of solid malignancies both *in vitro* and *in vivo* [18-23]. Furthermore, *HOX* expression has been shown to promote a number of aggressive tumour characteristics, including invasion and migration [24], DNA repair [25], and the induction of angiogenesis [26]. Consequently, the tumour expression of a number of *HOX* genes has been shown to be related to the survival of cancer patients [27].
Despite a number of excellent reviews on this subject, the HOX expression profiles of different cancer types generally remains unclear as it is difficult to directly compare the information in studies that have used different techniques to assess HOX expression, and some studies have given conflicting results. This review attempts to establish a broad overview of HOX expression in different solid malignancies by only including data on the over- or under-expression of HOX genes based on at least 2 different techniques (e.g. QPCR and immunohistochemistry), and which has been demonstrated in 2 different studies. The findings of this review for head and neck [24, 28-36], oesophageal [37, 38], gastric [39, 40], colorectal [41], pancreatic [42], hepatic [41], lung [43-46], breast [47], bladder [48, 49], renal [23], prostate [50, 51], and ovarian cancer [52-54] are summarized in Fig 1 and Table 1. It is striking that different tumour types show very different patterns of HOX expression. For example, gastric tumours tend to show very little HOX gene over-expression, whilst hepatic tumours exhibit a vastly dysregulated network of HOX genes. It also seems clear that different tumour types have radically different HOX gene expression patterns, with the notable exception of bladder and prostate tumours (Fig 1). These distinct, tumour-specific expression profiles make HOX genes potential markers of CTCs.

**HOX genes as CTC markers**

As discussed above, CTCs generally make up only a very small proportion blood cells. After excluding red blood cells, the majority of remaining cells are lymphocytes and monocytes. Both have previously been shown to express HOX genes, and indeed the expression of all 39 HOX genes has been studied in different lymphocyte and monocyte populations [55]. This revealed that monocytes, T-lymphocytes and B-lymphocytes expressed distinct but also overlapping sets of HOX genes, and also that HOX gene expression changed considerably upon activation of the cell types. In contrast, very little is known of HOX expression in other myeloid lineages, although previous studies have
suggested that *HOX* genes are generally down-regulated in mature blood cells [56]. In the context of possible CTC markers, these data are potentially very useful as they also reveal that a number of *HOX* genes are not expressed in normal lymphocytes or monocytes (Table 2). Despite the reduced number of *HOX* genes available for possible CTC identification, all tumour types appear to present with a distinct pattern of non-lymphocytic/monocytic *HOX* expression, except for bladder and prostate tumours (Fig 2). Based on these findings, it seems possible that *HOX* expression profiles could act as a “fingerprint” of specific tumour types, potentially allowing CTC detection without CTC isolation. For example, hepatic CTCs might be distinguished by their very high level of HOX dysregulation, whilst gastric CTCs appear to be characterized by high levels of HOXA13 expression in the absence of other HOX genes. Ovarian and pancreatic cancer is likewise distinguishable by the predominant expression of genes from the HOXB cluster, although the former expresses more posterior (5’) *HOX* genes than the latter. It should be noted that the data presented in this review are inevitably incomplete with respect to the expression of *HOX* genes in both cancer and normal blood cells. However, it is becoming apparent that there is high degree of differential HOX expression between mature blood cells and CTCs, pointing towards a nucleic acid based methodology for distinguishing between these cell types.
<table>
<thead>
<tr>
<th><strong>HOX genes</strong></th>
<th><strong>Cancer</strong></th>
<th><strong>Disease stage</strong></th>
<th><strong>Comparator</strong></th>
<th><strong>Reference</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HOXB9</strong></td>
<td>Head and neck</td>
<td></td>
<td>Immortalized normal oral keratinocytes, normal oral mucosa</td>
<td>[24]</td>
</tr>
<tr>
<td><strong>HOXA1</strong></td>
<td>Head and neck</td>
<td></td>
<td>Normal oral mucosa</td>
<td>[28]</td>
</tr>
<tr>
<td><strong>HOXB7</strong></td>
<td>Head and neck</td>
<td>I, II, III, IV</td>
<td>Normal oral mucosa</td>
<td>[29]</td>
</tr>
<tr>
<td><strong>HOXD10</strong></td>
<td>Head and neck</td>
<td>Primary, metastatic</td>
<td>Immortalized normal oral keratinocytes, normal oral mucosa</td>
<td>[30]</td>
</tr>
<tr>
<td><strong>HOXB5</strong></td>
<td>Head and neck</td>
<td>N0, N+</td>
<td>Normal oral mucosa</td>
<td>[31]</td>
</tr>
<tr>
<td><strong>HOXA10</strong></td>
<td>Head and neck</td>
<td>I, II, III, IV</td>
<td>Normal oral tissue</td>
<td>[32]</td>
</tr>
<tr>
<td><strong>HOXD10</strong></td>
<td>Head and neck</td>
<td></td>
<td>Immortalized normal oral keratinocytes, normal oral mucosa</td>
<td>[33]</td>
</tr>
<tr>
<td><strong>HOXC5</strong></td>
<td>Head and neck</td>
<td></td>
<td>Rat normal oral tissue</td>
<td>[34]</td>
</tr>
<tr>
<td><strong>HOXC6</strong></td>
<td>Head and neck</td>
<td></td>
<td>Normal tissue</td>
<td>[35]</td>
</tr>
<tr>
<td>HOX Gene</td>
<td>Cancer Type</td>
<td>Clinical Stages</td>
<td>Normal Tissue</td>
<td>Reference</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>----------------</td>
<td>---------------</td>
<td>-----------</td>
</tr>
<tr>
<td>HOXA10, A13, B7, C4, C8, D9, D10, D13</td>
<td>Oesophageal cancer</td>
<td>Iia, Iib, III</td>
<td>Normal oral mucosa</td>
<td>[37]</td>
</tr>
<tr>
<td>HOXD9</td>
<td>Oesophageal cancer</td>
<td>None</td>
<td></td>
<td>[38]</td>
</tr>
<tr>
<td>HOXA13</td>
<td>Gastric cancer</td>
<td>All T stages, metastasis</td>
<td>Normal mucosa</td>
<td>[39]</td>
</tr>
<tr>
<td>HOXC6</td>
<td>Gastric cancer</td>
<td></td>
<td>Normal mucosa</td>
<td>[40]</td>
</tr>
<tr>
<td>HOXA9, B3, B8, B9</td>
<td>Colorectal cancer</td>
<td>pT1, pT2, pT3, pT4</td>
<td>Normal colorectal mucosa</td>
<td>[41]</td>
</tr>
<tr>
<td>HOXA3, A5, A6, A7, A9, A10, A11, A13, B1, B6, B7, B8, B9, B13, C5, C6, C8, C9, C10, C11, C12, C13, D1, D3, D4, D8, D9, D10</td>
<td>Hepatic cancer</td>
<td>pl, plII, plIII, plIVa</td>
<td>Normal liver tissue adjacent to the tumour</td>
<td>[41]</td>
</tr>
<tr>
<td>HOXB2, B5, B6, B7</td>
<td>Pancreatic cancer</td>
<td>Pre-malignant pancreatic intraepithelial neoplasia, adenocarcinoma</td>
<td>Normal tissue</td>
<td>[42]</td>
</tr>
<tr>
<td>HOXA1, A5, A10, C6</td>
<td>Non-small cell lung cancer</td>
<td>pTNM: pT2(N0/1/2)M0 pStage: IB/IIB/IIIA</td>
<td>Normal tissue</td>
<td>[43]</td>
</tr>
<tr>
<td>HOXB9</td>
<td>Lung cancer</td>
<td>All clinical stages and TNM categories</td>
<td>Normal tissue</td>
<td>[46]</td>
</tr>
<tr>
<td>HOX Gene</td>
<td>Cancer Type</td>
<td>Disease Stage</td>
<td>Tissue Type</td>
<td>Reference</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>---------------</td>
<td>-------------</td>
<td>-----------</td>
</tr>
<tr>
<td>HOXA1</td>
<td>Small cell lung cancer</td>
<td>Extensive and limited disease</td>
<td>Normal lung alveoli epithelium</td>
<td>[45]</td>
</tr>
<tr>
<td>HOXA6, A13, B2, B4, B5, B6, B7, B8, B9, C5, C9, C13, D1, D8</td>
<td>Breast cancer</td>
<td></td>
<td>Non-malignant tissue</td>
<td>[47]</td>
</tr>
<tr>
<td>HOXB13</td>
<td>Bladder cancer</td>
<td>Muscle invasion</td>
<td>Non-invasive disease</td>
<td>[49]</td>
</tr>
<tr>
<td>HOXC4, C5, C6, C11</td>
<td>Bladder cancer</td>
<td></td>
<td>Normal uroepithelium</td>
<td>[48]</td>
</tr>
<tr>
<td>HOXB13</td>
<td>Prostate cancer</td>
<td></td>
<td>Normal prostate tissue</td>
<td>[50]</td>
</tr>
<tr>
<td>HOXC4, C5, C6, C8</td>
<td>Prostate cancer</td>
<td>Primary tumours, metastatic disease</td>
<td>Normal prostate epithelium, benign hypertrophy</td>
<td>[51]</td>
</tr>
<tr>
<td>HOXA10</td>
<td>Ovarian cancer</td>
<td></td>
<td>Normal ovarian tissue</td>
<td>[52]</td>
</tr>
<tr>
<td>HOXB7, B13</td>
<td>Ovarian cancer</td>
<td></td>
<td>Normal ovarian tissue</td>
<td>[53]</td>
</tr>
<tr>
<td>HOXB8</td>
<td>Ovarian cancer</td>
<td>Histological stages: high, low FIGO stages: IIIc, IV</td>
<td>Normal ovarian tissue</td>
<td>[54]</td>
</tr>
<tr>
<td>HOXA5, A9, B5, C9, D8, D9, D10</td>
<td>Renal cancer</td>
<td></td>
<td>Normal adjacent tissue</td>
<td>[23]</td>
</tr>
</tbody>
</table>
Table 2: HOX genes not expressed in normal lymphocytes or monocytes

<table>
<thead>
<tr>
<th>HOXA</th>
<th>HOXB</th>
<th>HOXC</th>
<th>HOXD</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOXA1</td>
<td>HOXB1</td>
<td>HOXC5</td>
<td>HOXD4</td>
</tr>
<tr>
<td>HOXA7</td>
<td>HOXB2</td>
<td>HOXC9</td>
<td>HOXD13</td>
</tr>
<tr>
<td>HOXA9</td>
<td>HOXB3</td>
<td>HOXC10</td>
<td></td>
</tr>
<tr>
<td>HOXA11</td>
<td>HOXB5</td>
<td>HOXC11</td>
<td></td>
</tr>
<tr>
<td>HOXA13</td>
<td>HOXB6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HOXB7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HOXB8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HOXB9</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HOXB13</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1: Summary of HOX gene expression in different solid malignancies.

Figure 2: Summary of HOX genes expressed in different solid malignancies that are not expressed in normal lymphocytes or monocytes.
References

Figure 1

- Head and neck
- Esophageal
- Gastric
- Colorectal
- Pancreatic
- Hepatic
- Lung
- Breast
- Bladder
- Renal
- Ovarian

Colors:
- HOXA
- HOXB
- HOXC
- HOXD
Figure 2

Head and neck

Gastric

Pancreatic

Lung

Bladder

Prostate

Esophageal

Colorectal

Hepatic

Breast

Renal

Ovarian

HOXA

HOXB

HOXC

HOXD